PL3823623T3 - Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu - Google Patents
Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemuInfo
- Publication number
- PL3823623T3 PL3823623T3 PL19768898.9T PL19768898T PL3823623T3 PL 3823623 T3 PL3823623 T3 PL 3823623T3 PL 19768898 T PL19768898 T PL 19768898T PL 3823623 T3 PL3823623 T3 PL 3823623T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- multiple sclerosis
- preventing multiple
- aminopyrimidine compound
- substituted aminopyrimidine
- Prior art date
Links
- -1 AMINOPYRIMIDINE COMPOUND Chemical class 0.000 title 1
- 201000006417 multiple sclerosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700977P | 2018-07-20 | 2018-07-20 | |
| US201862730184P | 2018-09-12 | 2018-09-12 | |
| US201962839273P | 2019-04-26 | 2019-04-26 | |
| PCT/IB2019/056198 WO2020016850A1 (en) | 2018-07-20 | 2019-07-19 | A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3823623T3 true PL3823623T3 (pl) | 2025-03-24 |
Family
ID=67953828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19768898.9T PL3823623T3 (pl) | 2018-07-20 | 2019-07-19 | Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US12251382B2 (pl) |
| EP (1) | EP3823623B1 (pl) |
| JP (1) | JP7724151B2 (pl) |
| KR (1) | KR20210034623A (pl) |
| CN (1) | CN112437665A (pl) |
| AU (2) | AU2019306828A1 (pl) |
| BR (1) | BR112021000893A2 (pl) |
| CA (1) | CA3106772A1 (pl) |
| DK (1) | DK3823623T3 (pl) |
| ES (1) | ES3009670T3 (pl) |
| FI (1) | FI3823623T3 (pl) |
| HR (1) | HRP20241737T1 (pl) |
| HU (1) | HUE069840T2 (pl) |
| IL (1) | IL280197A (pl) |
| MX (1) | MX2021000094A (pl) |
| PL (1) | PL3823623T3 (pl) |
| PT (1) | PT3823623T (pl) |
| SG (1) | SG11202100518TA (pl) |
| TW (1) | TWI879737B (pl) |
| UA (1) | UA127744C2 (pl) |
| WO (1) | WO2020016850A1 (pl) |
| ZA (1) | ZA202101118B (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021173740A1 (en) * | 2020-02-28 | 2021-09-02 | Genentech, Inc. | Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase |
| CN117320712A (zh) | 2021-05-14 | 2023-12-29 | 罗索肿瘤学公司 | 布鲁顿酪氨酸激酶抑制剂的共晶型 |
| US20240327379A1 (en) * | 2021-07-15 | 2024-10-03 | Sandoz Ag | Mandelate form of 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one |
| JP2025520698A (ja) | 2022-06-24 | 2025-07-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫疾患および炎症性疾患のための処置レジメン |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10060388A1 (de) * | 2000-12-05 | 2002-06-06 | Merck Patent Gmbh | Verwendung von Pyrazolo [4,3-d]pyrimidinen |
| WO2011156900A2 (en) * | 2010-06-17 | 2011-12-22 | Waratah Pharmaceuticals Inc. | Compounds, compositions and methods for treatment of multiple sclerosis |
| SG10201604682VA (en) * | 2011-06-10 | 2016-07-28 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| WO2013106535A1 (en) * | 2012-01-10 | 2013-07-18 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
| HRP20231547T1 (hr) | 2015-11-17 | 2024-03-15 | Merck Patent Gmbh | Postupci liječenja multiple skleroze primjenom spojeva pirimidina i piridina s aktivnošću inhibicije btk |
| US10464923B2 (en) * | 2017-02-27 | 2019-11-05 | Merck Patent Gmbh | Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone |
-
2019
- 2019-07-19 DK DK19768898.9T patent/DK3823623T3/da active
- 2019-07-19 TW TW108125526A patent/TWI879737B/zh active
- 2019-07-19 PL PL19768898.9T patent/PL3823623T3/pl unknown
- 2019-07-19 EP EP19768898.9A patent/EP3823623B1/en active Active
- 2019-07-19 JP JP2021503059A patent/JP7724151B2/ja active Active
- 2019-07-19 FI FIEP19768898.9T patent/FI3823623T3/fi active
- 2019-07-19 US US17/261,407 patent/US12251382B2/en active Active
- 2019-07-19 WO PCT/IB2019/056198 patent/WO2020016850A1/en not_active Ceased
- 2019-07-19 CA CA3106772A patent/CA3106772A1/en active Pending
- 2019-07-19 HU HUE19768898A patent/HUE069840T2/hu unknown
- 2019-07-19 UA UAA202100604A patent/UA127744C2/uk unknown
- 2019-07-19 MX MX2021000094A patent/MX2021000094A/es unknown
- 2019-07-19 CN CN201980048404.9A patent/CN112437665A/zh active Pending
- 2019-07-19 SG SG11202100518TA patent/SG11202100518TA/en unknown
- 2019-07-19 ES ES19768898T patent/ES3009670T3/es active Active
- 2019-07-19 PT PT197688989T patent/PT3823623T/pt unknown
- 2019-07-19 AU AU2019306828A patent/AU2019306828A1/en not_active Abandoned
- 2019-07-19 KR KR1020217004655A patent/KR20210034623A/ko active Pending
- 2019-07-19 HR HRP20241737TT patent/HRP20241737T1/hr unknown
- 2019-07-19 BR BR112021000893-4A patent/BR112021000893A2/pt unknown
-
2021
- 2021-01-14 IL IL280197A patent/IL280197A/en unknown
- 2021-02-18 ZA ZA2021/01118A patent/ZA202101118B/en unknown
-
2025
- 2025-05-05 AU AU2025203171A patent/AU2025203171A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| UA127744C2 (uk) | 2023-12-20 |
| ES3009670T3 (en) | 2025-03-31 |
| BR112021000893A2 (pt) | 2021-04-13 |
| CA3106772A1 (en) | 2020-01-23 |
| CN112437665A (zh) | 2021-03-02 |
| IL280197A (en) | 2021-03-01 |
| US20210260060A1 (en) | 2021-08-26 |
| DK3823623T3 (da) | 2025-01-02 |
| WO2020016850A1 (en) | 2020-01-23 |
| SG11202100518TA (en) | 2021-02-25 |
| EP3823623A1 (en) | 2021-05-26 |
| AU2025203171A1 (en) | 2025-05-22 |
| TWI879737B (zh) | 2025-04-11 |
| US12251382B2 (en) | 2025-03-18 |
| HUE069840T2 (hu) | 2025-04-28 |
| ZA202101118B (en) | 2025-06-25 |
| JP7724151B2 (ja) | 2025-08-15 |
| TW202019425A (zh) | 2020-06-01 |
| EP3823623B1 (en) | 2024-10-09 |
| HRP20241737T1 (hr) | 2025-02-28 |
| AU2019306828A1 (en) | 2021-03-11 |
| JP2021532104A (ja) | 2021-11-25 |
| FI3823623T3 (fi) | 2025-01-09 |
| PT3823623T (pt) | 2025-01-06 |
| MX2021000094A (es) | 2021-03-25 |
| KR20210034623A (ko) | 2021-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282487A (en) | Tyk2 inhibitors and uses thereof | |
| IL287223B1 (en) | kras g12c inhibitors and methods of using them | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| PL3661954T3 (pl) | Muteiny interleukiny 21 i sposoby leczenia | |
| KR102609396B9 (ko) | Ldha의 발현을 억제하기 위한 방법 및 조성물 | |
| IL283409A (en) | tyk2 inhibitors and uses thereof | |
| IL286248A (en) | Tyk2 inhibitors and uses thereof | |
| IL282350A (en) | Bernani-RGMC inhibitors and their use | |
| IL271863B (en) | Compounds and use thereof for the treatment of microbial infections | |
| PL3777419T3 (pl) | System i sposób zapewniania alokacji w dziedzinie czasu w systemie komunikacyjnym | |
| PL3484469T3 (pl) | Kompozycje i sposoby do wzmacniania działania środków przeciwdrobnoustrojowych | |
| EP4041212C0 (en) | MEK INHIBITORS FOR THE TREATMENT OF HANTAVIRUS INFECTIONS | |
| PL3464368T3 (pl) | Zastosowanie przeciwciała anty-pd-1 w skojarzeniu z przeciwciałem anty-cd30 w leczeniu chłoniaka | |
| MX2019006950A (es) | Metodos para tratar la sinaptopatia coclear. | |
| GB201820450D0 (en) | Compound and its use for the treatment of alpha1-antitryspin deficiency | |
| PL3823623T3 (pl) | Podstawiony związek aminopirymidynowy do zastosowania w metodzie leczenia i zapobiegania stwardnieniu rozsianemu | |
| EP4017924A4 (en) | SURFACE TREATMENT COMPOSITIONS AND METHODS | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| IL280348A (en) | Surface treatment compositions and methods | |
| PL3478719T3 (pl) | Stosowanie przeciwciał przeciw sklerostynie w leczeniu wrodzonej łamliwości kości | |
| IL271464A (en) | Nk-1 antagonist compositions and methods for use in treating depression | |
| EP3468555C0 (en) | COMPOSITIONS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| IT201600121601A1 (it) | Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo | |
| IT201700085412A1 (it) | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare |